Oregon launches legal psilocybin access to the public

Scientists developed new compounds derived from psilocybin, the active ingredient in “magic mushrooms”, that are designed to reduce the psychedelic effects associated with psilocybin while maintaining its therapeutic benefits.

Amanita Muscaria vs. Psychedelic Mushrooms (Psilocybin): What's the Difference?

Single-Dose Psilocybin for Major Depressive Disorder: Randomized Clinical Trial

Psychedelic psilocybin-assisted therapy reduces depressive symptoms in adults with cancer and depression

Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder was safe and feasible

Psilocybin analog leads to 79% of remission in mid-stage depression trial

Exploring the Impact of Psilocybin on the Immune System: Insights from a Controlled Study on Healthy Participants

Psilocybin-Assisted Therapy for Depression: A review and meta-Analysis finds psilocybin to have a significantly greater antidepressant effect compared to the placebo drug used

Psilocybin might be effective for treatment-resistant depression even with ongoing SSRI use, study suggests

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats

Benefits of psychedelics in obsessive-compulsive disorder: LSD and psilocybin have strong potential for providing long-lasting relief of patients’ symptoms

Psychedelic mushrooms and quiet quitting: Psilocybin use tied to working fewer overtime hours

Naturalistic psilocybin use associated with persisting improvement in wellbeing

Single-Dose Psilocybin Treatment for Major Depressive Disorder

Oregon launches legal psilocybin access amid high demand and hopes

"…found no detectable difference in altered states of consciousness induced by 20 mg psilocybin, 100 µg LSD, or 500 mg mescaline”, and no severe side effects were noted for any substance"

Review suggested that "psilocybin may be an effective form of treatment for cancer-related psychiatric distress, treatment-resistant depression and addiction" and that "there are some reports of psilocybin being useful when treating obsessive-compulsive disorder and cluster headaches."

Psilocybin Decelerates Cellular Senescence

A trial finds that a dose of the psychedelic psilocybin administered with psychological support is a safe and acceptable treatment for patients with anorexia nervosa and may decrease eating-disorder behaviours in some patients.

Psilocybin’s effects on cognition and creativity: A scoping review | Journal of Psychopharmacology [Jul 2023]

Australia to prescribe MDMA and psilocybin for PTSD and depression

A new study indicates that reductions in experiential avoidance play a significant role in the therapeutic effects of psilocybin-assisted therapy among depressed patients, leading to improvements in well-being and reductions in depression severity…

Spontaneous and deliberate creative cognition during and after psilocybin (2021)

Psychotherapy with Psilocybin for Depression: Systematic Review

Australia the First Nation to Approve the Legal Use of MDMA and Psilocybin

Psilocybin-enhanced group psychotherapy for depression shows promise in patients with cancer

The mechanism of psilocybin therapy: With psilocybin therapy, but not escitalopram, improvements in mental health outcomes (i.e., well-being, depression severity, suicidal ideation, and trait anxiety) occurred via reductions in experiential avoidance.

Patients tend to have a stronger brain response to music the day after receiving psilocybin-assisted therapy, according to new research

Preliminary study reveals potential of psilocybin for cluster headache treatment

More →